针对ncRNAs克服代谢重编程介导的癌症耐药性 (综述)
Junxin Li1, Yanyu Li1, Lin Fu1
1Department of Pharmacy, Zigong Fourth People's Hospital, Zigong, Sichuan 643000, P.R. China.
International journal of oncology
|March 21, 2025
概括
癌症中耐药性是一个主要的挑战. 非编码RNAs (ncRNAs) 调节癌细胞代谢,驱动耐药性,并为组合疗法提供新的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 癌症抗药性是一个重要的临床问题.
- 代谢重编程,包括改变的葡萄糖分解,脂质代谢,谷氨酸依赖和线粒体功能障碍,是癌症的标志,有助于药物耐药性.
- 非编码RNAs (ncRNAs) 在各种癌症中起着至关重要的作用,并与调节代谢途径有关.
研究的目的:
- 综合审查代谢重编程驱动癌症耐药性的机制.
- 强调ncRNAs在与药物耐药性相关的关键代谢变化中的调节作用.
- 讨论ncRNAs作为生物标志物和治疗点的潜力,以克服化疗耐药性.
主要方法:
- 文献综述和现有关于代谢重编程和ncRNAs在癌症药物耐药性的研究的综合.
- 对将ncRNA与代谢途径 (糖解,脂质代谢,谷氨酸代谢,线粒体功能) 联系起来的分子机制的分析.
- 探索ncRNAs作为化学疗法反应的预测生物标志物,以及作为新疗法策略的目标.
主要成果:
- 代谢重编程对癌症药物耐药性的多种分子机制有显著的贡献.
- ncRNAs是代谢异常的关键协调者,促进癌细胞的耐药性.
- 在药物耐药性的背景下,特定的ncRNAs调节糖解,脂质代谢,谷氨酸代谢和线粒体功能.
结论:
- ncRNAs是代谢重编程和癌症药物耐药性的关键调节者.
- 针对参与代谢途径的ncRNAs,为克服药物耐药性的组合疗法提供了一个有希望的策略.
- ncRNAs有可能作为预测患者对化疗反应的生物标志物.
更多相关视频
09:58Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
13.6K
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.5K
相关概念视频
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Transducer Mechanism: Nuclear Receptors
1.2K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.2K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
